{"database": "openregs", "table": "documents", "rows": [["FDA-2010-P-0614-0057", "FDA", "FDA-2010-P-0614", "Tab 19 - \"FDA/CDER Chemistry Review(s) for NDA 21-402, Synthroid\u00ae (levothyroxine sodium tablets, USP)\" - [Mutual Pharmaceutical Company, Inc. (Sidley Austin LLP) - Reply Comment]", "Supporting & Related Material", "RC-Reply Comment (Supporting and Related Material)", "2011-04-27T04:00:00Z", 2011, 4, null, null, "2011-04-27T19:20:40Z", null, 0, 0, "0900006480c27c6c"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2010-P-0614-0057"], "units": {}, "query_ms": 11.24113891273737, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}